Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PDS BiotechnologyFRA:EU6 -5.63%31 3-Year ROIIC % is 198.51 as of Dec. 2025. GuruFocus rates FRA:EU6 with a GF Score™ of 31/100. The stock has 1 warning sign investors should review. Among 1,323 Biotechnology companies, PDS Biotechnology ranks better than 84.2% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
PDS Biotechnology's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 198.51%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for PDS Biotechnology's 3-Year ROIIC % or its related term are showing as below:
FRA:EU6's 3-Year ROIIC % is ranked better than 84.2% of 1323
companies
in the Biotechnology industry
Industry Median: -4.85
vs FRA:EU6: 198.51
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
PDS Biotechnology 3-Year ROIIC % Related Terms
PDS Biotechnology 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for PDS Biotechnology's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:EU6 vs LTRN, AURX, VERU: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, PDS Biotechnology's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PDS Biotechnology 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PDS Biotechnology's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where PDS Biotechnology's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
PDS Biotechnology (FRA:EU6) has a 3-Year ROIIC % of 198.51 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on PDS Biotechnology and its competitors. According to the industry distribution chart, PDS Biotechnology ranks #209 out of 1323 companies in the Biotechnology industry, placing it in the top 15.8%.
Is PDS Biotechnology's 3-Year ROIIC % too high?
PDS Biotechnology's current 3-Year ROIIC % is 198.51. Based on the distribution chart, PDS Biotechnology ranks #209 out of 1323 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, PDS Biotechnology has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does PDS Biotechnology's 3-Year ROIIC % compare to LTRN and AURX?
According to the Biotechnology industry distribution chart, PDS Biotechnology ranks #209 out of 1323 companies for 3-Year ROIIC %. This places PDS Biotechnology in the top 16% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on PDS Biotechnology and its competitors. PDS Biotechnology's current 3-Year ROIIC % is 198.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PDS Biotechnology stock overvalued right now?
PDS Biotechnology (FRA:EU6) has a current 3-Year ROIIC % of 198.51. The current 3-Year ROIIC % is 198.51. PDS Biotechnology's overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For PDS Biotechnology (FRA:EU6), the current 3-Year ROIIC % is 198.51 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.
31GF Score
Get the complete analysis for FRA:EU6
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:EU6 has been successfully added to your 
